Cue Biopharma Raises $50 Million While Carrying Active Going Concern Warning
Distressed
Company Background
Cue Biopharma is a Boston-based clinical-stage biopharmaceutical company focused on immunological disorders. Its two lead programs are CUE-221, a Phase 2 anti-IgE antibody for allergic disease licensed from Ascendant Health Sciences in April 2026, and CUE-401, a bifunctional cytokine candidate advancing toward a Phase 1 study. Revenue is almost entirely collaboration-derived — $5.7 million in the first quarter of 2026, up sharply from $0.4 million in the prior-year period due to the Boehringer Ingelheim partnership — but the company remains deeply loss-making, with a net loss of $5.2 million in Q1 2026 and $26.6 million for full-year 2025.
The company has been in near-continuous governance flux. Two CEOs turned over in under seven months: Usman Azam resigned on March 26, 2026, and Lucinda Warren served as interim before Dr. Shao-Lee Lin was appointed President and CEO on April 30, 2026. Four directors — Jill Broadfoot, Peter Kiener, Frank Morich, and Patrick Verheyen — resigned simultaneously on May 29, 2026, reducing the board from seven to five members. Two replacements, Daniel Camardo and Viola Meehan, were added shortly after. A 1-for-30 reverse stock split was effected on April 23, 2026 to cure a Nasdaq minimum bid-price deficiency.
The company's cash position has been under sustained pressure. At December 31, 2025, it held $27.1 million; by March 31, 2026, that had fallen to $16.4 million. Subsequent inflows — a $30 million private placement and a $7.5 million milestone from Boehringer Ingelheim for compound selection under the CUE-501 program — temporarily replenished the balance sheet, but a going concern determination has been carried through multiple consecutive filings.
What Was Disclosed
On July 9, 2026, Cue Biopharma entered into a securities purchase agreement with accredited investors for a private placement of 1,418,071 shares of common stock at $33.21 per share, plus pre-funded warrants to purchase up to 87,500 additional shares at $33.209 apiece, raising approximately $50 million in gross proceeds. The offering was led by Cormorant Asset Management, with Columbia Threadneedle Investments among the participating new investors. Closing is expected on July 13, 2026. The pre-funded warrants carry an exercise price of $0.001 per share and are immediately exercisable, with standard beneficial-ownership blockers at 4.99% or 9.99% as elected by each holder. Management stated the net proceeds will be used to fund clinical development and for general corporate purposes.